Fig 1.

Achieved low density lipoprotein cholesterol (LDL-C) level and risk of cardiovascular disease (CVD) or atherosclerotic CVD (ASCVD) events by (A) subgroups from placebo-controlled statin trials of approximately a mean 5 years duration in the presence of coronary heart disease (CHD), metabolic syndrome (MS), impaired glucose tolerance (IGT) or diabetes (Adapted from Robinson JG, Stone NJ. Am J Cardiol 2006; 98:1405–1408); and subgroups categorized according to extrapolated 10-year ASCVD event rates from (B) moderate versus high intensity statin trials of a mean 3–5 years duration extrapolated to 5 years, and (C) PCSK9 inhibiting monoclonal antibody trials with a mean 2.2–2.8 years duration extrapolated to 5 years; Line represents log linear regression line for relationship between on-treatment LDL-C level and cardiovascular event rate weighted by group size.